Moderna, Inc.
MRNA US
MRNA USModerna, Inc.
United States Composite111.22
- Business
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Company News
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Analysts Are Bullish on Top Healthcare Stocks: Veeva Systems (VEEV), Moderna (MRNA)
Why Moderna (MRNA) Dipped More Than Broader Market Today
Why Moderna (MRNA) Dipped More Than Broader Market Today
Is Moderna Stock Going to $214? 1 Wall Street Analyst Thinks So.
Moderna Stock: Buy, Sell, or Hold?
Stock Market News for Apr 1, 2024
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Better Cathie Wood Stock: Moderna vs. Intellia
Is Moderna Stock A Buy As The Company Eyes The Covid Vaccine Market — Again?
Blackstone cures two ailments in one Moderna shot
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study